Orchestra BioMed - חוב לטווח קצר להון OBIO

Orchestra BioMed (OBIO) relies on the support of Medtronic, which provides the company with significant market weight and stable demand for the BackBeat system. The stock price history demonstrates the dynamics of the asset, whose metric is 0.00. Orchestra BioMed is developing advanced catheter-based treatments, deploying its platforms through industry leaders and expanding its portfolio of solutions to combat hypertension and cardiac pathologies.

This indicator assesses the company's reliance on short-term borrowings, determining liquidity risk for obligations maturing within one year. By analyzing the ratio of current loans to equity, an investor can identify the balance sheet's sensitivity to interest rate fluctuations. An increase in this metric signals a rising debt load, while a decrease confirms financial stability. For Orchestra BioMed (OBIO), stable royalties from Medtronic minimize the need for short-term express loans.